SAFETY AND EFFICACY RESULTS FROM A PHASE 1/1B STUDY OF INTRATUMORAL MK-4621, A RETINOIC ACID-INDUCIBLE GENE I (RIG-I) AGONIST, PLUS INTRAVENOUS PEMBROLIZUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS

被引：0

作者：

Moreno, Victor ^{[1
]}

Gaudy-Marqueste, Caroline ^{[2
]}

Wermke, Martin ^{[3
]}

Italiano, Antoine ^{[4
]}

Romano, Emanuela ^{[5
]}

Marabelle, Aurelien ^{[6
]}

Connors, Emilee ^{[7
]}

Zhou, Heng ^{[7
]}

Dobrenkov, Konstantin ^{[7
]}

Chartash, Elliot ^{[7
]}

Calvo, Emiliano ^{[8
]}

Calvo Aller, Emiliano ^{[8
]}

机构：

[1] Hosp Univ Fdn Jimenez, ISTART Madrid FJD, Madrid, Spain

[2] Timones Hosp, CEPCM CLIP2, Marseille, France

[3] Univ Klinikum Carl Gustav Carus, Dresden, Germany

[4] Inst Bergonie, Bordeaux, France

[5] Inst Curie, Paris, France

[6] Inst Gustave Roussy, Villejuif, France

[7] Merck & Co Inc, Kenilworth, NJ USA

[8] Ctr Integral Onco, START Madrid CIOCC, Madrid, Spain

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2020年 / 8卷

关键词：

D O I：

10.1136/jitc-2020-SITC2020.0794

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

794

引用

页码：A474 / A475

页数：2

共 50 条

[21] Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma Phase 1b Results From the JAVELIN Solid Tumor Trial
Hassan, Raffit
Thomas, Anish
Nemunaitis, John J.
Patel, Manish R.
Bennouna, Jaafar
Chen, Franklin L.
Delord, Jean-Pierre
Dowlati, Afshin
Kochuparambil, Samith T.
Taylor, Matthew H.
Powderly, John D.
Vaishampayan, Ulka N.
Verschraegen, Claire
Grote, Hans Juergen
von Heydebreck, Anja
Chin, Kevin
Gulley, James L.
JAMA ONCOLOGY, 2019, 5 (03) : 351 - 357
[22] Final results from a phase I study to evaluate the safety and efficacy of a telomerasespecific oncolytic adenovirus (OBP301) with pembrolizumab in patients with advanced solid tumors (EPOC1505)
Kojima, Takashi
Fujiwara, Toshiyoshi
Tanabe, Shunsuke
Kadota, Tomoyuki
Ono, Hiromi
Tsukamoto, Kazuko
Ikeno, Takashi
Wakabayashi, Masashi
Sato, Akihiro
Kondo, Masanori
Kumagai, Shogo
Koyama, Shohei
Nishikawa, Hiroyoshi
Doi, Toshihiko
CANCER RESEARCH, 2023, 83 (08)
[23] Safety and Efficacy in Advanced Solid Tumors of a Targeted Nanocomplex Carrying the p53 Gene Used in Combination with Docetaxel: A Phase 1b Study
Pirollo, Kathleen F.
Nemunaitis, John
Leung, Po Ki
Nunan, Robert
Adams, Jana
Chang, Esther H.
MOLECULAR THERAPY, 2016, 24 (09) : 1697 - 1706
[24] Phase 1a/1b study design of the novel STING agonist, immune-stimulating antibodyconjugate (ISAC) TAK-500, with or without pembrolizumab in patients with advanced solid tumors
Diamond, Jennifer Robinson
Henry, Jason Timothy
Falchook, Gerald Steven
Olszanski, Anthony J.
Singh, Harshabad
Leonard, E. Jane
Gregory, Richard C.
Appleman, Vicky A.
Gibbs, John
Harbison, Carole
Li, Cong
Sapiro, Jessica M.
Yoneyama, Tomoki
Parent, Alexander A.
Chung, Vincent
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[25] The safety and tolerability of epacadostat alone and in combination with pembrolizumab in patients with advanced solid tumors: results from a first-in-Japanese phase I study (KEYNOTE-434)
Doi, Toshihiko
Fujiwara, Yutaka
Shitara, Kohei
Shimizu, Toshio
Yonemori, Kan
Matsubara, Nobuaki
Ohno, Izumi
Kogawa, Takahiro
Naito, Yoichi
Leopold, Lance
Munteanu, Mihaela
Yatsuzuka, Naoyoshi
Han, Shi Rong
Samkari, Ayman
Yamamoto, Noboru
INVESTIGATIONAL NEW DRUGS, 2021, 39 (01) : 152 - 162
[26] The safety and tolerability of epacadostat alone and in combination with pembrolizumab in patients with advanced solid tumors: results from a first-in-Japanese phase I study (KEYNOTE-434)
Toshihiko Doi
Yutaka Fujiwara
Kohei Shitara
Toshio Shimizu
Kan Yonemori
Nobuaki Matsubara
Izumi Ohno
Takahiro Kogawa
Yoichi Naito
Lance Leopold
Mihaela Munteanu
Naoyoshi Yatsuzuka
Shi Rong Han
Ayman Samkari
Noboru Yamamoto
Investigational New Drugs, 2021, 39 : 152 - 162
[27] Safety and efficacy of the PD-1 inhibitor ABBV-181 in patients with advanced solid tumors: Preliminary phase I results from study M15-891
Powderly, J.
Cassier, P. A.
Cervantes, A.
Gao, B.
Gazzah, A.
Italiano, A.
Lin, C-C.
Luke, J. J.
Moreno, V.
Peltola, K.
Rasco, D.
Spira, A. I.
Tanner, M. M. E.
Tosi, D.
Afar, D.
Englert, S.
Parikh, A.
Reddy, A.
Vosganian, G.
Tolcher, A. W.
ANNALS OF ONCOLOGY, 2018, 29 : 144 - 144
[28] EFFICACY AND SAFETY OF GX-I7 PLUS PEMBROLIZUMAB FOR HEAVILY PRETREATED PATIENTS WITH METASTATIC TRIPLE NEGATIVE BREAST CANCER: THE PHASE 1B/2 KEYNOTE-899 STUDY
Sohn, Joo
Im, Young Hyuk
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A197 - A198
[29] Safety and preliminary activity of naptumomab estafenatox (NAP) and durvalumab in patients with advanced or metastatic solid tumors: interim results from a phase 1b trial
Geva, Ravit
Stemmer, Salomon
Perets, Ruth
Maurice-Dror, Corinne
Ben-Ami, Eitan
Raphael, Ari
Kumar, Sanjeev
Lorber, Ilana
Kedem, Tal Hetzroni
Fields, Scott Z.
Rozencweig, Marcel
Golan, Talia
CANCER RESEARCH, 2023, 83 (08)
[30] A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA study
Silk, Ann W.
O'Day, Steven J.
Kaufman, Howard L.
Bryan, Jennifer
Norrell, Jacqueline T.
Imbergamo, Casey
Portal, Daniella
Zambrano-Acosta, Edwin
Palmeri, Marisa
Fein, Seymour
Wu, Cai
Guerreiro, Leslie
Medina, Daniel
Bommareddy, Praveen K.
Zloza, Andrew
Fox, Bernard A.
Ballesteros-Merino, Carmen
Ren, Yixin
Shafren, Darren
Grose, Mark
Vieth, Joshua A.
Mehnert, Janice M.
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (06) : 1405 - 1415

← 1 2 3 4 5 →